New hope for Hard-to-Treat myeloma: experimental drug enters human trials

NCT ID NCT06433947

Recruiting now Disease control Sponsor: Opna Bio LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called OPN-6602, alone or with a steroid, in 130 people whose multiple myeloma has returned or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. It's too early to know if it will work, but researchers hope it may offer a new option for patients who have run out of standard therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OPN-6602 (a targeted drug) and dexamethasone (a steroid)
What this could lead to: If successful, this could lead to a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is an early Phase 1 trial with only 130 participants, focused mainly on safety. The drug may not work well or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MULTIPLE MYELOMA RELAPSED MULTIPLE MYELOMA

Contacts and locations

Locations

Banner MD Anderson
RECRUITING

Gilbert, Arizona, 85234, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Emory Winchip Cancer Center
RECRUITING

Atlanta, Georgia, 30322, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Huntsman Cancer Center Institute University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
Stanford Cancer Institute
RECRUITING

Stanford, California, 94305, United States
UC San Diego Moores Cancer Center
RECRUITING

La Jolla, California, 92093-0698, United States
University of Kansas Clinical Research Center
RECRUITING

Westwood, Kansas, 66205, United States
University of North Carolina Hospitals at Hillsborough
RECRUITING

Chapel Hill, North Carolina, 27599, United States
University of Rochester Medical Center
RECRUITING

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.